선택지 정리됨
Appendiceal cancer / pseudomyxoma peritonei: 국가별 선택지
이 페이지는 한국어 임상 치료 설명을 새로 쓰지 않습니다. 권위 출처, 진료 전 정리 질문, 임상시험 검색어, 구축 상태를 보여주는 안전한 시작점입니다.
선택지 정리됨고형암최종 확인 2026.06
현재 제공
국가별 선택지를 정리합니다
국가별로 출처가 연결된 선택지와 함께, 진단명·단계·검사 결과·진료과·임상시험 검색어를 정리합니다.
아직 하지 않음
치료 선택을 지시하지 않습니다
이 페이지는 치료 순위, 권장, 적합성 판단을 하지 않습니다.
출처
공신력 있는 출처 기반
모든 선택지는 규제·평가·지침 등 공신력 있는 출처에 연결되며, 새 출처가 검증되면 계속 확장됩니다.
진료 전 정리할 정보
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
임상시험 검색어
국가별 선택지
국가별 치료 선택지
공식 규제·평가 기관 출처를 바탕으로 한 국가별 승인·접근 상태입니다. 무엇이 어디에 존재하는지를 보여줄 뿐, 추천이 아닙니다.
United States
- Appendectomy, hemicolectomy, cytoreductive/debulking surgery, systemic chemotherapy, intraperitoneal chemotherapy including EPIC and HIPEC, radiation therapy rarely[1]Standard option (per Memorial Sloan Kettering Cancer Center)Localized appendiceal cancer; carcinoid tumor larger than 2 cm hemicolectomy context; later-stage/spread appendiceal cancer; chemotherapy before/after debulking; rare radiation context if spread to other organs. · This is a single academic-center treatment page, not a national guideline or regulator source. It does not establish that a specific operation, chemotherapy regimen, or radiation approach is appropriate for any individual case. Confidence/conflicts: Medium-high for treatment category mapping; no conflict with NCI, but MSK provides more procedure detail than the NCI rare-tumor overview.
- Appendectomy, hemicolectomy, cytoreductive/debulking surgery, systemic chemotherapy, intraperitoneal chemotherapy including EPIC and HIPEC, radiation therapy rarely[1]Standard option (per Memorial Sloan Kettering Cancer Center)Localized appendiceal cancer; carcinoid tumor larger than 2 cm hemicolectomy context; later-stage/spread appendiceal cancer; chemotherapy before/after debulking; rare radiation context if spread to other organs. · This is a single academic-center treatment page, not a national guideline or regulator source. It does not establish that a specific operation, chemotherapy regimen, or radiation approach is appropriate for any individual case. Confidence/conflicts: Medium-high for treatment category mapping; no conflict with NCI, but MSK provides more procedure detail than the NCI rare-tumor overview.
- Appendectomy, hemicolectomy, cytoreductive/debulking surgery, systemic chemotherapy, intraperitoneal chemotherapy including EPIC and HIPEC, radiation therapy rarely[1]Standard option (per Memorial Sloan Kettering Cancer Center)Localized appendiceal cancer; carcinoid tumor larger than 2 cm hemicolectomy context; later-stage/spread appendiceal cancer; chemotherapy before/after debulking; rare radiation context if spread to other organs. · This is a single academic-center treatment page, not a national guideline or regulator source. It does not establish that a specific operation, chemotherapy regimen, or radiation approach is appropriate for any individual case. Confidence/conflicts: Medium-high for treatment category mapping; no conflict with NCI, but MSK provides more procedure detail than the NCI rare-tumor overview.
- Appendectomy, hemicolectomy, cytoreductive/debulking surgery, systemic chemotherapy, intraperitoneal chemotherapy including EPIC and HIPEC, radiation therapy rarely[1]Standard option (per Memorial Sloan Kettering Cancer Center)Localized appendiceal cancer; carcinoid tumor larger than 2 cm hemicolectomy context; later-stage/spread appendiceal cancer; chemotherapy before/after debulking; rare radiation context if spread to other organs. · This is a single academic-center treatment page, not a national guideline or regulator source. It does not establish that a specific operation, chemotherapy regimen, or radiation approach is appropriate for any individual case. Confidence/conflicts: Medium-high for treatment category mapping; no conflict with NCI, but MSK provides more procedure detail than the NCI rare-tumor overview.
- Surgery to remove appendix and affected abdominal or pelvic organs/tissue; chemotherapy; hyperthermic intraperitoneal chemotherapy (HIPEC)[2]Standard option (per National Cancer Institute)Appendiceal cancer; chemotherapy/HIPEC context when cancer has spread to other parts of the abdomen. · NCI does not provide a stage-by-stage protocol on this page and emphasizes expert evaluation. The page does not establish insurance coverage, center availability, drug choice for HIPEC, or individual surgical suitability. Confidence/conflicts: High for the broad U.S. treatment categories and expert-care caveat; low for regimen-specific details because NCI does not specify them on this page.
- Surgery to remove appendix and affected abdominal or pelvic organs/tissue; chemotherapy; hyperthermic intraperitoneal chemotherapy (HIPEC)[2]Standard option (per National Cancer Institute)Appendiceal cancer; chemotherapy/HIPEC context when cancer has spread to other parts of the abdomen. · NCI does not provide a stage-by-stage protocol on this page and emphasizes expert evaluation. The page does not establish insurance coverage, center availability, drug choice for HIPEC, or individual surgical suitability. Confidence/conflicts: High for the broad U.S. treatment categories and expert-care caveat; low for regimen-specific details because NCI does not specify them on this page.
- Surgery to remove appendix and affected abdominal or pelvic organs/tissue; chemotherapy; hyperthermic intraperitoneal chemotherapy (HIPEC)[2]Standard option (per National Cancer Institute)Appendiceal cancer; chemotherapy/HIPEC context when cancer has spread to other parts of the abdomen. · NCI does not provide a stage-by-stage protocol on this page and emphasizes expert evaluation. The page does not establish insurance coverage, center availability, drug choice for HIPEC, or individual surgical suitability. Confidence/conflicts: High for the broad U.S. treatment categories and expert-care caveat; low for regimen-specific details because NCI does not specify them on this page.
- Surgery to remove appendix and affected abdominal or pelvic organs/tissue; chemotherapy; hyperthermic intraperitoneal chemotherapy (HIPEC)[2]Standard option (per National Cancer Institute)Appendiceal cancer; chemotherapy/HIPEC context when cancer has spread to other parts of the abdomen. · NCI does not provide a stage-by-stage protocol on this page and emphasizes expert evaluation. The page does not establish insurance coverage, center availability, drug choice for HIPEC, or individual surgical suitability. Confidence/conflicts: High for the broad U.S. treatment categories and expert-care caveat; low for regimen-specific details because NCI does not specify them on this page.
United Kingdom
- Watch and wait/active surveillance, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), debulking surgery, chemotherapy, specialist-centre treatment[3]Standard option (per Cancer Research UK)PMP; slow-growing/small disease monitoring context; CRS/HIPEC where possible; debulking or chemotherapy where appropriate. · CRS/HIPEC is described as major, intensive surgery requiring fitness and resectability assessment. The page does not prove NHS commissioning for an individual patient or specify universal eligibility. Confidence/conflicts: High for UK PMP treatment categories and specialist-centre note; no NICE source was separately fetched in this finding, so NICE details remain link-through rather than independently extracted.
- Watch and wait/active surveillance, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), debulking surgery, chemotherapy, specialist-centre treatment[3]Standard option (per Cancer Research UK)PMP; slow-growing/small disease monitoring context; CRS/HIPEC where possible; debulking or chemotherapy where appropriate. · CRS/HIPEC is described as major, intensive surgery requiring fitness and resectability assessment. The page does not prove NHS commissioning for an individual patient or specify universal eligibility. Confidence/conflicts: High for UK PMP treatment categories and specialist-centre note; no NICE source was separately fetched in this finding, so NICE details remain link-through rather than independently extracted.
- Watch and wait/active surveillance, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), debulking surgery, chemotherapy, specialist-centre treatment[3]Standard option (per Cancer Research UK)PMP; slow-growing/small disease monitoring context; CRS/HIPEC where possible; debulking or chemotherapy where appropriate. · CRS/HIPEC is described as major, intensive surgery requiring fitness and resectability assessment. The page does not prove NHS commissioning for an individual patient or specify universal eligibility. Confidence/conflicts: High for UK PMP treatment categories and specialist-centre note; no NICE source was separately fetched in this finding, so NICE details remain link-through rather than independently extracted.
- Watch and wait/active surveillance, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), debulking surgery, chemotherapy, specialist-centre treatment[3]Standard option (per Cancer Research UK)PMP; slow-growing/small disease monitoring context; CRS/HIPEC where possible; debulking or chemotherapy where appropriate. · CRS/HIPEC is described as major, intensive surgery requiring fitness and resectability assessment. The page does not prove NHS commissioning for an individual patient or specify universal eligibility. Confidence/conflicts: High for UK PMP treatment categories and specialist-centre note; no NICE source was separately fetched in this finding, so NICE details remain link-through rather than independently extracted.
출처
- Memorial Sloan Kettering Cancer Center — academic cancer-center treatment information · academic cancer-center treatment information
- National Cancer Institute — national cancer agency rare-tumor information · national cancer agency rare-tumor information
- Cancer Research UK — UK cancer information / guideline-referenced treatment information · UK cancer information / guideline-referenced treatment information
위 내용은 공식 규제·접근 상태일 뿐, 의학적 조언이나 추천이 아니고, 적격성을 판단하지도 않습니다. 어떤 선택지가 적합한지는 환자의 상황과 종양내과 팀에 달려 있습니다. 규제 상태는 바뀔 수 있으니 표시된 출처에서 확인하세요. 임상 세부 내용은 영문이 정본입니다. 최종 확인 2026-06-12.